Pharma in review: trending stories 9/13/19

Sep 13, 2019

number1

FDA commish frontrunner emerges

MD Anderson Cancer Center exec Stephen Hahn has emerged as the frontrunner for FDA commissioner. 


number2Mallinckrodt offloads BioVectra for $250 million
Mallinckrodt will sell its subsidiary, BioVectra, to an affiliate of H.I.G. Capita for $250 million.

 

number3Amgen experimental lung cancer drug shows promise

More than half of patients with an advanced form of lung cancer initially responded to an experimental Amgen drug.

 

number4

Novartis investigational lung cancer therapy grabs breakthrough status

                  The U.S. FDA has granted Breakthrough Therapy designation to Novartis' capmatinib.

 

number5

BMS Opdivo fails in brain cancer study

Bristol-Myers said its blockbuster immunotherapy failed to meet a main goal of a late-stage trial.